177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 949-955

  Rasaneh, Samira ^a   Rajabi, Hossein ^a   Babaei, Mohammad Hossein ^b   Daha, Fariba Johari ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Department of Radioisotope Nuclear Science   (Iran)

Author keywords

Biodistribution; Breast cancer; Cytotoxicity; DOTA; Herceptin; Lutetium 177

Indexed keywords

DIAGNOSTIC AGENT; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB;

ANIMAL; ARTICLE; BREAST TUMOR; DRUG SCREENING; FEMALE; METHODOLOGY; MOUSE; PATHOLOGY; QUALITY CONTROL; RADIOIMMUNOTHERAPY; REPRODUCIBILITY; SCINTISCANNING; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; LUTETIUM; MICE; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 78049486362     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.07.001     Document Type: Article

References (26)

1. Sharkey R.M., Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005, 46:115-127.
2. Albanell J., Codony J., Rovira A., Mellado B., Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Bio 2003, 532:253-268.
3. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Slamon D.J., Fendly B.M., et al. Expressionof the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990, 45(3):457-461.
4. Metro G., Mottolese M., Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2008, 9(15):2583-2601.
5. 188Re-herceptin. Nucl Med Biol 2005, 32(1):59-65.
6. 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol 2009, 36(1):81-88.
7. Costantini D.L., Chan C., Cai Z., Vallis K.A., Reilly R.M. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007, 48(8):1357-1368.
8. 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 2006, 33(3):333-347.
9. Palm S., Enmon R.M., Matei C., Kolbert K.S., Xu S., Zanzonico P.B., et al. Pharmacokinetics and biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003, 44(7):1148-1155.
10. Davoli A., Hocevar B.A., Brown T.L. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 2010, 65(4):611-623.
11. Seidman A., Hudis C., Pierri M., Shak S., Paton V., Ashby M. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
12. Fleck L.M. The costs of caring: Who pays? Who profits? Who panders?. Hastings Cent Rep 2006, 36(3):13-17.
13. 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2009, 36(4):363-369.
14. Rasaneh S, Rajabi H, Babaei MH, Johari-Daha F, Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines, Appl Radiat Isotopes, In Press, 12 May 2010.
15. Koyama Y., Barrett T., Hama Y., Ravizzini G., Choyke P.L., Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor targeted optically labeled monoclonal antibodies. Neoplasia 2007, 9(12):1021-1029.
16. 90Y labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 2007, 34:493-502.
17. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2007, 34:173-183.
18. Brady E.D., Chong H.S., Milenic D.E., Brechbiel M.W. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. J Nucl Med 2004, 31:795-802.
19. Lowry O.H., Rosebrough N.J., Farr L., Randal R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-269.
20. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.J. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
21. Johnstone T., Thorpe R. Immunocytochemistry, immunohistochemistry and flow cytofluorimetry. Immunochemistry in practice 1996, 313-380. Blackwell Science, Berlin. 3rd ed.
22. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
24. Nayak D., Lahiri S. Application of radioisotopes in the field of nuclear medicine. J Radioanal Nucl Chem 1999, 242:423-432.
25. 186Re. J Nucl Med 2004, 45:327-337.
26. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005, 46:850-858.